BRVE · Braveheart Bio, Inc.
Market Cap
$2.00B
Shares
90.04M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$29.41
Open$27.18
Day$27.18–29.91
Available close range$25.01–30.00
Avg vol available · 23d496K
Short int848K · 0.9% float · 1.3d
Short vol69%
Last earningsSep 8, 2026
DataAug 2026–Sep 2026
Filing10-Q · Sep 8
The closing range uses available history since Aug 6, 2026; less than a full year is stored.
Up next
filed Sep 8, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$122.83M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+165.1%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.9%
Latest settlement · 1.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Limited
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.7 · calm
Equity put/call 0.48
Technical
price trend
50 / 200-day cross
No cross
RSI (14)
53
neutral
52-week position
88%
near high
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$159.0M over 90 days · 0% sells
Short interest
Rising
0.94% of float · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
49
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−17%
past year
ATR
8.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
RSI (14)
53
Neutral
52-week position
88%
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$159.0M over 90 days · 0% sells
Short interest
Rising
0.94% of float · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its available closing range
Range low $25
Now $29 · 88%
Range high $30
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BRVE
this stock
Braveheart Bio, Inc.
|
$2.00B | — | — | — | 0.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.42B | +16.7% | +46.2% | 31.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.15B | +5.0% | +20.8% | 20.0 | 2.3% |
|
ARGX
Argenx SE
|
$62.63B | +19.8% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.54B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Smart Money
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BRVE | +15.3% | +6.8% | — | +15.3% | — |
| SPY | -0.1% | -0.9% | +14.2% | -0.1% | +12.3% |
| vs SPY | +15.5% | +7.7% | — | +15.5% | — |